Latest Pharma Insights
AASLD 2026: Regeneron, GSK, Merck Look To Bring Competition In MASH
Potential rivals to Madrigal and Novo in metabolic dysfunction-associated steatohepatitis (MASH) update their programs for the field, while Vir and Mirum position themselves to take on Gilead in hepatitis D.
Scrip - November 10, 2026
Potential rivals to Madrigal and Novo in metabolic dysfunction-associated steatohepatitis (MASH) update their programs for the field, while Vir and Mirum position themselves to take on Gilead in hepatitis D.
Scrip - November 10, 2026
Finance Watch: Proximal Ventures Backs AI-Based Life Sciences Solutions With New Fund
Private Company Edition: Proximal founder and managing partner Sahir Raoof discusses the firm’s first fund which has $27.5m for AI start-ups that may help deliver better drugs faster. Also, Delix closed a $100m series C round, while Graviton and CinRx launched CinRock.
Scrip - November 10, 2026
Private Company Edition: Proximal founder and managing partner Sahir Raoof discusses the firm’s first fund which has $27.5m for AI start-ups that may help deliver better drugs faster. Also, Delix closed a $100m series C round, while Graviton and CinRx launched CinRock.
Scrip - November 10, 2026
Impact of Theranos Still Haunts Diagnostics Companies, Say Leaders At Babson And Truvian
A decade after Theranos’s collapse, the blood testing industry is still dealing with leftover stains that include wary investors. However, the added scrutiny has also raised standards, say leaders from Truvian and Babson Diagnostics.
Medtech Insight - November 10, 2026
A decade after Theranos’s collapse, the blood testing industry is still dealing with leftover stains that include wary investors. However, the added scrutiny has also raised standards, say leaders from Truvian and Babson Diagnostics.
Medtech Insight - November 10, 2026
Q3 Earnings Roundup: Roivant, Ionis, Lundbeck
Roivant’s Lisraya hit the ground running; Ionis’s shares fell on slower Tryngolza sales growth; and Lundbeck raised its revenue guidance for the 2026 fiscal year.
Scrip - November 10, 2026
Roivant’s Lisraya hit the ground running; Ionis’s shares fell on slower Tryngolza sales growth; and Lundbeck raised its revenue guidance for the 2026 fiscal year.
Scrip - November 10, 2026
Senate Committee To Vote On US FDA Commissioner Nominee Before Dem Takeover
Outgoing Senate Health, Education, Labor and Pensions Committee Chair Bill Cassidy is planning a vote on Heidi Overton's nomination for FDA commissioner, while Acting Commissioner Kyle Diamantas' future plans remain undertermined.
Medtech Insight - November 10, 2026
Outgoing Senate Health, Education, Labor and Pensions Committee Chair Bill Cassidy is planning a vote on Heidi Overton's nomination for FDA commissioner, while Acting Commissioner Kyle Diamantas' future plans remain undertermined.
Medtech Insight - November 10, 2026
DOJ’s FCA Self-Disclosure Pilot Not A One-and-Done Remedy
The DOJ's voluntary disclosure pilot program will let life science companies avoid some of the more severe penalties associated with FCA cases. But pilot participants should sustain a robust compliance program because future federal prosecutors will remain aware of the initial concerns.
Medtech Insight - November 10, 2026
The DOJ's voluntary disclosure pilot program will let life science companies avoid some of the more severe penalties associated with FCA cases. But pilot participants should sustain a robust compliance program because future federal prosecutors will remain aware of the initial concerns.
Medtech Insight - November 10, 2026
Scientific Questions Remain As Aumseqa Heads For New EU Verdict Just Weeks After Revocation
Hansoh’s lung cancer drug, Aumseqa, is heading for a possible new EU approval recommendation just weeks after its original marketing approval was unprecedentedly revoked, raising questions about how the European Medicines Agency has reassessed the scientific evidence supporting the application.
Pink Sheet - November 10, 2026
Hansoh’s lung cancer drug, Aumseqa, is heading for a possible new EU approval recommendation just weeks after its original marketing approval was unprecedentedly revoked, raising questions about how the European Medicines Agency has reassessed the scientific evidence supporting the application.
Pink Sheet - November 10, 2026
Boehringer Ready To File Survodutide But At What Threat To Obesity Leaders?
A cardiovascular outcomes trial has completed the survodutide dataset, but has not clarified the drug’s value compared with the market leading GLP-1 based therapies.
Scrip - November 10, 2026
A cardiovascular outcomes trial has completed the survodutide dataset, but has not clarified the drug’s value compared with the market leading GLP-1 based therapies.
Scrip - November 10, 2026
Rivia Adds AI-Powered Data Checks To Clinical Trial Platform
Clinical trial data management is becoming a new frontier for AI, as Rivia looks to automate one of drug development's most time-consuming operational tasks.
Scrip - November 10, 2026
Clinical trial data management is becoming a new frontier for AI, as Rivia looks to automate one of drug development's most time-consuming operational tasks.
Scrip - November 10, 2026
No Silver Bullet Exists To Fix API Supply-Chain Fragility In The US
At the AAM’s GRx+Biosims conference, panelists debated strategies surrounding how to make the generics and biosimilar supply chain more resilient, amid geopolitical pressures and wider behavioral changes from both producers and purchasers.
Generics Bulletin - November 10, 2026
At the AAM’s GRx+Biosims conference, panelists debated strategies surrounding how to make the generics and biosimilar supply chain more resilient, amid geopolitical pressures and wider behavioral changes from both producers and purchasers.
Generics Bulletin - November 10, 2026
Consumer Products Across Categories Should Ride ‘Wellness Takeover’ For Growth – McKinsey Report
“The wellness takeover” across regions and demographics as consumers worldwide rank wellness second-highest priority, behind family, consulting firm states in “Future of Wellness 2027: Inside the $2.7 trillion takeover.”
HBW Insight - November 10, 2026
“The wellness takeover” across regions and demographics as consumers worldwide rank wellness second-highest priority, behind family, consulting firm states in “Future of Wellness 2027: Inside the $2.7 trillion takeover.”
HBW Insight - November 10, 2026
Bayer All Set For Sunharbo Launch As Stroke Drug Seals FDA Okay
The oral Factor XIa inhibitor is vital to the German major’s efforts to limit the damage of Xarelto and Eylea losing patent protection.
Scrip - November 10, 2026
The oral Factor XIa inhibitor is vital to the German major’s efforts to limit the damage of Xarelto and Eylea losing patent protection.
Scrip - November 10, 2026
Lupin Doubles Down On US Growth As Competition To Key Generic Assets Dents Q2
Lupin plans to double complex products' share of its US portfolio, as generic competition erodes tolvaptan and mirabegron revenues. Meanwhile, other developed markets grew by 46%, with Europe being the champion of the quarter.
Generics Bulletin - November 10, 2026
Lupin plans to double complex products' share of its US portfolio, as generic competition erodes tolvaptan and mirabegron revenues. Meanwhile, other developed markets grew by 46%, with Europe being the champion of the quarter.
Generics Bulletin - November 10, 2026
MDR 2.0: Recertifications Remain A Sticking Point In Negotiations
In an exclusive interview, Team-NB’s president, Alexey Shiryaev, says that notified bodies want predictability from MDR and IVDR revisions but are open to changes to how recertifications work. The European Commission says its proposal keeps a risk-adaptive approach to oversight.
Medtech Insight - November 10, 2026
In an exclusive interview, Team-NB’s president, Alexey Shiryaev, says that notified bodies want predictability from MDR and IVDR revisions but are open to changes to how recertifications work. The European Commission says its proposal keeps a risk-adaptive approach to oversight.
Medtech Insight - November 10, 2026
Pipeline Watch: Three Approvals And Eleven Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - November 10, 2026
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - November 10, 2026
Early-Stage Biotech Is Not Waiting For The Money To Come Back
Mega-rounds dominate biotech venture funding, so early-stage founders are adapting with bigger seeds, cheaper geographies, leaner science and creative financing rather than awaiting a rebound.
In Vivo - November 10, 2026
Mega-rounds dominate biotech venture funding, so early-stage founders are adapting with bigger seeds, cheaper geographies, leaner science and creative financing rather than awaiting a rebound.
In Vivo - November 10, 2026
Strategic Intent: Lundbeck On Reimbursement, Risk And The Return Of Neuroscience
In this episode of Strategic Intent, Maria Alfaiate, Executive Vice President for Corporate Portfolio and Product Strategy at Lundbeck, discusses neuroscience's growing resurgence in pharmaceutical investment alongside other challenges faced in central nervous system dealmaking decisions.
In Vivo - November 10, 2026
In this episode of Strategic Intent, Maria Alfaiate, Executive Vice President for Corporate Portfolio and Product Strategy at Lundbeck, discusses neuroscience's growing resurgence in pharmaceutical investment alongside other challenges faced in central nervous system dealmaking decisions.
In Vivo - November 10, 2026
Respiratory Today, Oncology Tomorrow: Glenmark Lines Up Its Next Chapter
Glenmark is betting on Ryaltris rollouts and the first US generic of GSK’s Flovent HFA to drive respiratory gains, while a Hansoh-licensed lung cancer drug lines up its first oncology launch and partnered oncology assets progress, but a returned dermatology asset tempers its pipeline.
Generics Bulletin - November 10, 2026
Glenmark is betting on Ryaltris rollouts and the first US generic of GSK’s Flovent HFA to drive respiratory gains, while a Hansoh-licensed lung cancer drug lines up its first oncology launch and partnered oncology assets progress, but a returned dermatology asset tempers its pipeline.
Generics Bulletin - November 10, 2026
Video Interview: The Future of CDMOs: Integrated Development and Complex Modalities
Lupin Manufacturing Solutions explains how integrated API, formulation, and manufacturing capabilities can help CDMOs tackle complex modalities like peptides and ADCs.
Scrip - November 10, 2026
Lupin Manufacturing Solutions explains how integrated API, formulation, and manufacturing capabilities can help CDMOs tackle complex modalities like peptides and ADCs.
Scrip - November 10, 2026
ACR 2026: Novartis/Abogen’s mRNA T-Cell Engager Shows Initial Promise In Scleroderma
In an investigator-initiated trial in Chinese scleroderma patients, ABO2203 caused no cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome, and there were also early efficacy signals.
Scrip - November 10, 2026
In an investigator-initiated trial in Chinese scleroderma patients, ABO2203 caused no cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome, and there were also early efficacy signals.
Scrip - November 10, 2026
Astellas Employee Imprisoned In China Reportedly Released Next Month
After serving 3.5 years in prison in China following charges under the country's updated anti-espionage law, an Astellas employee will reportedly be released next month.
Scrip - November 10, 2026
After serving 3.5 years in prison in China following charges under the country's updated anti-espionage law, an Astellas employee will reportedly be released next month.
Scrip - November 10, 2026
Cultivating An iPSC Ecosystem: RACTHERA CEO On Japan Cell Therapy Journey
Established as a joint venture by Sumitomo Chemical and Sumitomo Pharma, RACTHERA won a global-first conditional approval in Japan for an induced pluripotent stem cell therapy earlier this year, for Amchepry for Parkinson’s. CEO Atsushi Ikeda reveals the backstory on the iPSC pivot.
Scrip - November 10, 2026
Established as a joint venture by Sumitomo Chemical and Sumitomo Pharma, RACTHERA won a global-first conditional approval in Japan for an induced pluripotent stem cell therapy earlier this year, for Amchepry for Parkinson’s. CEO Atsushi Ikeda reveals the backstory on the iPSC pivot.
Scrip - November 10, 2026
FDA Discussion Paper Weighs Benefit-Risk For Autonomous And Remote Surgical Robots
With autonomous and remotely operated surgical robots fast approaching, a US FDA discussion paper offers a first look at the considerations the agency expects to apply in evaluating the benefits and risks of those devices.
Medtech Insight - November 10, 2026
With autonomous and remotely operated surgical robots fast approaching, a US FDA discussion paper offers a first look at the considerations the agency expects to apply in evaluating the benefits and risks of those devices.
Medtech Insight - November 10, 2026
AASLD 2026: Regeneron, GSK, Merck Look To Bring Competition In MASH
Potential rivals to Madrigal and Novo in metabolic dysfunction-associated steatohepatitis (MASH) update their programs for the field, while Vir and Mirum position themselves to take on Gilead in hepatitis D.
Scrip - November 10, 2026
Potential rivals to Madrigal and Novo in metabolic dysfunction-associated steatohepatitis (MASH) update their programs for the field, while Vir and Mirum position themselves to take on Gilead in hepatitis D.
Scrip - November 10, 2026
Finance Watch: Proximal Ventures Backs AI-Based Life Sciences Solutions With New Fund
Private Company Edition: Proximal founder and managing partner Sahir Raoof discusses the firm’s first fund which has $27.5m for AI start-ups that may help deliver better drugs faster. Also, Delix closed a $100m series C round, while Graviton and CinRx launched CinRock.
Scrip - November 10, 2026
Private Company Edition: Proximal founder and managing partner Sahir Raoof discusses the firm’s first fund which has $27.5m for AI start-ups that may help deliver better drugs faster. Also, Delix closed a $100m series C round, while Graviton and CinRx launched CinRock.
Scrip - November 10, 2026
Q3 Earnings Roundup: Roivant, Ionis, Lundbeck
Roivant’s Lisraya hit the ground running; Ionis’s shares fell on slower Tryngolza sales growth; and Lundbeck raised its revenue guidance for the 2026 fiscal year.
Scrip - November 10, 2026
Roivant’s Lisraya hit the ground running; Ionis’s shares fell on slower Tryngolza sales growth; and Lundbeck raised its revenue guidance for the 2026 fiscal year.
Scrip - November 10, 2026
Scientific Questions Remain As Aumseqa Heads For New EU Verdict Just Weeks After Revocation
Hansoh’s lung cancer drug, Aumseqa, is heading for a possible new EU approval recommendation just weeks after its original marketing approval was unprecedentedly revoked, raising questions about how the European Medicines Agency has reassessed the scientific evidence supporting the application.
Pink Sheet - November 10, 2026
Hansoh’s lung cancer drug, Aumseqa, is heading for a possible new EU approval recommendation just weeks after its original marketing approval was unprecedentedly revoked, raising questions about how the European Medicines Agency has reassessed the scientific evidence supporting the application.
Pink Sheet - November 10, 2026
Boehringer Ready To File Survodutide But At What Threat To Obesity Leaders?
A cardiovascular outcomes trial has completed the survodutide dataset, but has not clarified the drug’s value compared with the market leading GLP-1 based therapies.
Scrip - November 10, 2026
A cardiovascular outcomes trial has completed the survodutide dataset, but has not clarified the drug’s value compared with the market leading GLP-1 based therapies.
Scrip - November 10, 2026
Rivia Adds AI-Powered Data Checks To Clinical Trial Platform
Clinical trial data management is becoming a new frontier for AI, as Rivia looks to automate one of drug development's most time-consuming operational tasks.
Scrip - November 10, 2026
Clinical trial data management is becoming a new frontier for AI, as Rivia looks to automate one of drug development's most time-consuming operational tasks.
Scrip - November 10, 2026
Bayer All Set For Sunharbo Launch As Stroke Drug Seals FDA Okay
The oral Factor XIa inhibitor is vital to the German major’s efforts to limit the damage of Xarelto and Eylea losing patent protection.
Scrip - November 10, 2026
The oral Factor XIa inhibitor is vital to the German major’s efforts to limit the damage of Xarelto and Eylea losing patent protection.
Scrip - November 10, 2026
Pipeline Watch: Three Approvals And Eleven Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - November 10, 2026
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - November 10, 2026
Video Interview: The Future of CDMOs: Integrated Development and Complex Modalities
Lupin Manufacturing Solutions explains how integrated API, formulation, and manufacturing capabilities can help CDMOs tackle complex modalities like peptides and ADCs.
Scrip - November 10, 2026
Lupin Manufacturing Solutions explains how integrated API, formulation, and manufacturing capabilities can help CDMOs tackle complex modalities like peptides and ADCs.
Scrip - November 10, 2026
ACR 2026: Novartis/Abogen’s mRNA T-Cell Engager Shows Initial Promise In Scleroderma
In an investigator-initiated trial in Chinese scleroderma patients, ABO2203 caused no cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome, and there were also early efficacy signals.
Scrip - November 10, 2026
In an investigator-initiated trial in Chinese scleroderma patients, ABO2203 caused no cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome, and there were also early efficacy signals.
Scrip - November 10, 2026
Astellas Employee Imprisoned In China Reportedly Released Next Month
After serving 3.5 years in prison in China following charges under the country's updated anti-espionage law, an Astellas employee will reportedly be released next month.
Scrip - November 10, 2026
After serving 3.5 years in prison in China following charges under the country's updated anti-espionage law, an Astellas employee will reportedly be released next month.
Scrip - November 10, 2026
Cultivating An iPSC Ecosystem: RACTHERA CEO On Japan Cell Therapy Journey
Established as a joint venture by Sumitomo Chemical and Sumitomo Pharma, RACTHERA won a global-first conditional approval in Japan for an induced pluripotent stem cell therapy earlier this year, for Amchepry for Parkinson’s. CEO Atsushi Ikeda reveals the backstory on the iPSC pivot.
Scrip - November 10, 2026
Established as a joint venture by Sumitomo Chemical and Sumitomo Pharma, RACTHERA won a global-first conditional approval in Japan for an induced pluripotent stem cell therapy earlier this year, for Amchepry for Parkinson’s. CEO Atsushi Ikeda reveals the backstory on the iPSC pivot.
Scrip - November 10, 2026
Impact of Theranos Still Haunts Diagnostics Companies, Say Leaders At Babson And Truvian
A decade after Theranos’s collapse, the blood testing industry is still dealing with leftover stains that include wary investors. However, the added scrutiny has also raised standards, say leaders from Truvian and Babson Diagnostics.
Medtech Insight - November 10, 2026
A decade after Theranos’s collapse, the blood testing industry is still dealing with leftover stains that include wary investors. However, the added scrutiny has also raised standards, say leaders from Truvian and Babson Diagnostics.
Medtech Insight - November 10, 2026
Senate Committee To Vote On US FDA Commissioner Nominee Before Dem Takeover
Outgoing Senate Health, Education, Labor and Pensions Committee Chair Bill Cassidy is planning a vote on Heidi Overton's nomination for FDA commissioner, while Acting Commissioner Kyle Diamantas' future plans remain undertermined.
Medtech Insight - November 10, 2026
Outgoing Senate Health, Education, Labor and Pensions Committee Chair Bill Cassidy is planning a vote on Heidi Overton's nomination for FDA commissioner, while Acting Commissioner Kyle Diamantas' future plans remain undertermined.
Medtech Insight - November 10, 2026
DOJ’s FCA Self-Disclosure Pilot Not A One-and-Done Remedy
The DOJ's voluntary disclosure pilot program will let life science companies avoid some of the more severe penalties associated with FCA cases. But pilot participants should sustain a robust compliance program because future federal prosecutors will remain aware of the initial concerns.
Medtech Insight - November 10, 2026
The DOJ's voluntary disclosure pilot program will let life science companies avoid some of the more severe penalties associated with FCA cases. But pilot participants should sustain a robust compliance program because future federal prosecutors will remain aware of the initial concerns.
Medtech Insight - November 10, 2026
MDR 2.0: Recertifications Remain A Sticking Point In Negotiations
In an exclusive interview, Team-NB’s president, Alexey Shiryaev, says that notified bodies want predictability from MDR and IVDR revisions but are open to changes to how recertifications work. The European Commission says its proposal keeps a risk-adaptive approach to oversight.
Medtech Insight - November 10, 2026
In an exclusive interview, Team-NB’s president, Alexey Shiryaev, says that notified bodies want predictability from MDR and IVDR revisions but are open to changes to how recertifications work. The European Commission says its proposal keeps a risk-adaptive approach to oversight.
Medtech Insight - November 10, 2026
FDA Discussion Paper Weighs Benefit-Risk For Autonomous And Remote Surgical Robots
With autonomous and remotely operated surgical robots fast approaching, a US FDA discussion paper offers a first look at the considerations the agency expects to apply in evaluating the benefits and risks of those devices.
Medtech Insight - November 10, 2026
With autonomous and remotely operated surgical robots fast approaching, a US FDA discussion paper offers a first look at the considerations the agency expects to apply in evaluating the benefits and risks of those devices.
Medtech Insight - November 10, 2026
Consumer Products Across Categories Should Ride ‘Wellness Takeover’ For Growth – McKinsey Report
“The wellness takeover” across regions and demographics as consumers worldwide rank wellness second-highest priority, behind family, consulting firm states in “Future of Wellness 2027: Inside the $2.7 trillion takeover.”
HBW Insight - November 10, 2026
“The wellness takeover” across regions and demographics as consumers worldwide rank wellness second-highest priority, behind family, consulting firm states in “Future of Wellness 2027: Inside the $2.7 trillion takeover.”
HBW Insight - November 10, 2026
No Silver Bullet Exists To Fix API Supply-Chain Fragility In The US
At the AAM’s GRx+Biosims conference, panelists debated strategies surrounding how to make the generics and biosimilar supply chain more resilient, amid geopolitical pressures and wider behavioral changes from both producers and purchasers.
Generics Bulletin - November 10, 2026
At the AAM’s GRx+Biosims conference, panelists debated strategies surrounding how to make the generics and biosimilar supply chain more resilient, amid geopolitical pressures and wider behavioral changes from both producers and purchasers.
Generics Bulletin - November 10, 2026
Lupin Doubles Down On US Growth As Competition To Key Generic Assets Dents Q2
Lupin plans to double complex products' share of its US portfolio, as generic competition erodes tolvaptan and mirabegron revenues. Meanwhile, other developed markets grew by 46%, with Europe being the champion of the quarter.
Generics Bulletin - November 10, 2026
Lupin plans to double complex products' share of its US portfolio, as generic competition erodes tolvaptan and mirabegron revenues. Meanwhile, other developed markets grew by 46%, with Europe being the champion of the quarter.
Generics Bulletin - November 10, 2026
Respiratory Today, Oncology Tomorrow: Glenmark Lines Up Its Next Chapter
Glenmark is betting on Ryaltris rollouts and the first US generic of GSK’s Flovent HFA to drive respiratory gains, while a Hansoh-licensed lung cancer drug lines up its first oncology launch and partnered oncology assets progress, but a returned dermatology asset tempers its pipeline.
Generics Bulletin - November 10, 2026
Glenmark is betting on Ryaltris rollouts and the first US generic of GSK’s Flovent HFA to drive respiratory gains, while a Hansoh-licensed lung cancer drug lines up its first oncology launch and partnered oncology assets progress, but a returned dermatology asset tempers its pipeline.
Generics Bulletin - November 10, 2026
Early-Stage Biotech Is Not Waiting For The Money To Come Back
Mega-rounds dominate biotech venture funding, so early-stage founders are adapting with bigger seeds, cheaper geographies, leaner science and creative financing rather than awaiting a rebound.
In Vivo - November 10, 2026
Mega-rounds dominate biotech venture funding, so early-stage founders are adapting with bigger seeds, cheaper geographies, leaner science and creative financing rather than awaiting a rebound.
In Vivo - November 10, 2026
Strategic Intent: Lundbeck On Reimbursement, Risk And The Return Of Neuroscience
In this episode of Strategic Intent, Maria Alfaiate, Executive Vice President for Corporate Portfolio and Product Strategy at Lundbeck, discusses neuroscience's growing resurgence in pharmaceutical investment alongside other challenges faced in central nervous system dealmaking decisions.
In Vivo - November 10, 2026
In this episode of Strategic Intent, Maria Alfaiate, Executive Vice President for Corporate Portfolio and Product Strategy at Lundbeck, discusses neuroscience's growing resurgence in pharmaceutical investment alongside other challenges faced in central nervous system dealmaking decisions.
In Vivo - November 10, 2026